Innovations

Study shows heart failure treatment with dapagliflozin consistently benefited both men and women

0
Close Up Scientist using microscope in laboratory room while making medical testing and research

When it comes to heart failure (HF), sex differences are known to impact everything from risk factors to clinical presentation to response to treatment, making sex a key factor to consider in studies of emerging pharmacotherapies. Sodium-glucose cotransporter-2 (SGLT2) inhibitors, such as dapagliflozin, have become an important pharmacotherapy solution for patients with HF, yet more data are needed to assess their effect and safety between sexes.

Major life stressors may worsen long COVID symptoms

Previous article

Other defibrillation strategies studied for refractory V-fib

Next article

You may also like

Comments

Leave a reply

Your email address will not be published. Required fields are marked *

More in Innovations